Basilea Pharmaceutica AG
SIX:BSLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
ReTo Eco-Solutions Inc
NASDAQ:RETO
|
CN |
Basilea Pharmaceutica AG
Cash from Operating Activities
Basilea Pharmaceutica AG
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Cash from Operating Activities
CHf62.1m
|
CAGR 3-Years
106%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Cash from Operating Activities
-$141.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Cash from Operating Activities
-$345m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Cash from Operating Activities
-CHf153.2m
|
CAGR 3-Years
44%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Cash from Operating Activities
-CHf455k
|
CAGR 3-Years
63%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Cash from Operating Activities
-CHf3.5m
|
CAGR 3-Years
52%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
Glance View
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.
See Also
What is Basilea Pharmaceutica AG's Cash from Operating Activities?
Cash from Operating Activities
62.1m
CHF
Based on the financial report for Dec 31, 2025, Basilea Pharmaceutica AG's Cash from Operating Activities amounts to 62.1m CHF.
What is Basilea Pharmaceutica AG's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
106%
Over the last year, the Cash from Operating Activities growth was -17%. The average annual Cash from Operating Activities growth rates for Basilea Pharmaceutica AG have been 106% over the past three years .
